Cannabis, CBD industry wary of looming decision on epilepsy drug

Published April 9, 2018 | By Kristen NicholsThe most disruptive product to hit the newly legal hemp industry might be one that will never be sold directly to consumers.GW Pharmaceuticals, a London-based biotech company, is awaiting a final decision from the U.S. Food and Drug Administration to produce the first cannabis-derived treatment to win approval …

The Next Big Brain Cancer Drug Could Come from Marijuana

Sy Mukherjee 9:44 PM Central GW Pharmaceuticals (gwph, +2.63%) is already well on its way to winning the first-ever U.S. approval for a cannabis-derived therapy. But an early trial suggests that these treatments could also be an effective way to fight one of most devastating forms of brain cancers: glioblastoma multiforme. The U.K.-based company unveiled …

The Bayer-Monsanto Deal Won’t Eat the Cannabis Industry. Yet.

Submitted by Marijuana News on Fri, 09/16/2016 - 08:10   The news that Monsanto is being bought by Bayer probably won’t be well received in the cannabis sector. The deal brings together two research powerhouses that, reportedly, have long eyed cannabis as a possible new business. The worry is that the combined firm will have …